ReviewFrontiers in pharmacology2026
Inter-organ crosstalk in systemic inflammation: a narrative review of molecular mechanisms and pharmacological modulation in the muscle-adipose-liver axis.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic inflammation is increasingly recognized as a network-driven process sustained by dynamic inter-organ communication rather than isolated tissue responses. The muscle-adipose-liver axis plays a central role in this framework, integrating metabolic and immune signals that regulate systemic homeostasis. During inflammatory conditions, this coordinated communication becomes dysregulated, contributing to insulin resistance, chronic inflammation, and multi-organ dysfunction. Inter-organ crosstalk is mediated by multiple interconnected signaling layers, including cytokines, extracellular vesicles, lipid mediators, and metabolites, which collectively shape local and systemic responses. Emerging evidence highlights the importance of extracellular vesicles as long-distance carriers of molecular information, as well as the role of lipid mediators and metabolic reprogramming in linking inflammation with metabolic pathways. Pharmacological modulation of these networks represents a promising therapeutic strategy. While current interventions targeting cytokines and metabolic pathways show systemic benefits, newer approaches focusing on extracellular vesicle signaling and pro-resolving lipid mediators offer opportunities for more precise and context-dependent treatments. Advances in multi-omics and systems pharmacology are further enabling the identification of key regulatory nodes and biomarkers, supporting the development of precision medicine strategies. Overall, understanding and targeting inter-organ communication networks may provide more integrative and effective approaches for the treatment of systemic inflammatory and metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.